979 related articles for article (PubMed ID: 27239107)
21. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.
de Mattos BR; Garcia MP; Nogueira JB; Paiatto LN; Albuquerque CG; Souza CL; Fernandes LG; Tamashiro WM; Simioni PU
Mediators Inflamm; 2015; 2015():493012. PubMed ID: 26339135
[TBL] [Abstract][Full Text] [Related]
22. The Search for Causative Environmental Factors in Inflammatory Bowel Disease.
Rogler G; Zeitz J; Biedermann L
Dig Dis; 2016; 34 Suppl 1():48-55. PubMed ID: 27548430
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.
Karmiris K; Avgerinos A; Tavernaraki A; Zeglinas C; Karatzas P; Koukouratos T; Oikonomou KA; Kostas A; Zampeli E; Papadopoulos V; Theodoropoulou A; Viazis N; Polymeros D; Michopoulos S; Bamias G; Kapsoritakis A; Karamanolis DG; Mantzaris GJ; Tzathas C; Koutroubakis IE
J Crohns Colitis; 2016 Apr; 10(4):429-36. PubMed ID: 26721936
[TBL] [Abstract][Full Text] [Related]
24. Clinical features of hidradenitis suppurativa and Crohn disease: what do these two entities have in common?
Vilarrasa Rull E; González Lama Y
Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():21-26. PubMed ID: 28081766
[TBL] [Abstract][Full Text] [Related]
25. [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].
Ochsenkühn T; Sackmann M; Göke B
Radiologe; 2003 Jan; 43(1):1-8. PubMed ID: 12552369
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of inflammatory bowel disease among pediatric patients with hidradenitis suppurativa and the potential role of screening with fecal calprotectin.
Lloyd-McLennan AM; Ali S; Kittler NW
Pediatr Dermatol; 2021 Jan; 38(1):98-102. PubMed ID: 33099810
[TBL] [Abstract][Full Text] [Related]
28. Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
Dumont LM; Landman C; Sokol H; Beaugerie L; Cosnes J; Seksik P; Guégan S;
Aliment Pharmacol Ther; 2020 Jul; 52(2):303-310. PubMed ID: 32525586
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors for Developing Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Retrospective Case-Control Study.
Tandon P; Govardhanam V; Gallinger Z; Weizman AV
J Can Assoc Gastroenterol; 2021 Aug; 4(4):165-172. PubMed ID: 34337316
[TBL] [Abstract][Full Text] [Related]
30. The evolving epidemiology of inflammatory bowel disease.
Shanahan F; Bernstein CN
Curr Opin Gastroenterol; 2009 Jul; 25(4):301-5. PubMed ID: 19349861
[TBL] [Abstract][Full Text] [Related]
31. Epidemiology of hidradenitis suppurativa and inflammatory bowel disease: are these two disease associated?
Salgado-Boquete L; Romaní J; Carrión L; Marín-Jiménez I
Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():8-12. PubMed ID: 28081771
[TBL] [Abstract][Full Text] [Related]
32. Classical and recent advances in the treatment of inflammatory bowel diseases.
Sales-Campos H; Basso PJ; Alves VB; Fonseca MT; Bonfá G; Nardini V; Cardoso CR
Braz J Med Biol Res; 2015 Feb; 48(2):96-107. PubMed ID: 25466162
[TBL] [Abstract][Full Text] [Related]
33. Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.
Severs M; van Erp SJ; van der Valk ME; Mangen MJ; Fidder HH; van der Have M; van Bodegraven AA; de Jong DJ; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; Ponsioen CY; Bolwerk C; Vermeijden JR; Pierik MJ; Siersema PD; Leenders M; van der Meulen-de Jong AE; Dijkstra G; Oldenburg B;
J Crohns Colitis; 2016 Apr; 10(4):455-61. PubMed ID: 26721937
[TBL] [Abstract][Full Text] [Related]
34. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003.
Hutfless SM; Weng X; Liu L; Allison J; Herrinton LJ
Gastroenterology; 2007 Dec; 133(6):1779-86. PubMed ID: 18054550
[TBL] [Abstract][Full Text] [Related]
35. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases.
Sobczak M; Fabisiak A; Murawska N; Wesołowska E; Wierzbicka P; Wlazłowski M; Wójcikowska M; Zatorski H; Zwolińska M; Fichna J
Pharmacol Rep; 2014 Oct; 66(5):766-75. PubMed ID: 25149979
[TBL] [Abstract][Full Text] [Related]
36. Ophthalmic manifestations in patients with inflammatory bowel disease: A review.
Troncoso LL; Biancardi AL; de Moraes HV; Zaltman C
World J Gastroenterol; 2017 Aug; 23(32):5836-5848. PubMed ID: 28932076
[TBL] [Abstract][Full Text] [Related]
37. Skin Manifestations of Inflammatory Bowel Disease.
Greuter T; Navarini A; Vavricka SR
Clin Rev Allergy Immunol; 2017 Dec; 53(3):413-427. PubMed ID: 28643285
[TBL] [Abstract][Full Text] [Related]
38. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
39. Systemic associations of hidradenitis suppurativa.
Kohorst JJ; Kimball AB; Davis MD
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S27-35. PubMed ID: 26470611
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the French Vasculitis Study Group.
Humbert S; Guilpain P; Puéchal X; Terrier B; Rivière S; Mahr A; Pagnoux C; Bagnères D; Cordier JF; Le Quellec A; Altwegg R; Guillevin L;
Rheumatology (Oxford); 2015 Nov; 54(11):1970-5. PubMed ID: 26106214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
